C–C chemokine receptor type 2 mediates glomerular injury and interstitial fibrosis in focal segmental glomerulosclerosis
Open Access
- 28 December 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 35 (2) , 227-239
Abstract
Glomerulosclerosis and tubulointerstitial fibrosis are hallmarks of chronic kidney injury leading to end-stage renal disease. Inflammatory mechanisms contribute to glomerular and interstitial scarring, including chemokine-mediated recruitment of leucocytes. In particular, accumulation of C–C chemokine receptor type 2 (CCR2)-expressing macrophages promotes renal injury and fibrotic remodelling in diseases like glomerulonephritis and diabetic nephropathy. The functional role of CCR2 in the initiation and progression of primary glomerulosclerosis induced by podocyte injury remains to be characterized. We analysed glomerular expression of CCR2 and its chemokine ligand C–C motif chemokine ligand 2 (CCL2) in human focal segmental glomerulosclerosis (FSGS). Additionally, CCL2 expression was determined in stimulated murine glomeruli and glomerular cells in vitro. To explore pro-inflammatory and profibrotic functions of CCR2 we induced adriamycin nephropathy, a murine model of FSGS, in BALB/c wild-type and Ccr2-deficient mice. Glomerular expression of CCR2 and CCL2 significantly increased in human FSGS. In adriamycin-induced FSGS, progressive glomerular scarring and reduced glomerular nephrin expression was paralleled by induced glomerular expression of CCL2. Adriamycin exposure stimulated secretion of CCL2 and tumour necrosis factor-α (TNF) in isolated glomeruli and mesangial cells and CCL2 in parietal epithelial cells. In addition, TNF induced CCL2 expression in all glomerular cell populations, most prominently in podocytes. In vivo, Ccr2-deficient mice with adriamycin nephropathy showed reduced injury, macrophage and fibrocyte infiltration and inflammation in glomeruli and the tubulointerstitium. Importantly, glomerulosclerosis and tubulointerstitial fibrosis were significantly ameliorated. Our data indicate that CCR2 is an important mediator of glomerular injury and progression of FSGS. CCR2- targeting therapies may represent a novel approach for its treatment.Keywords
Funding Information
- Faculty of Medicine, Ludwig-Maximilians-Universität München
This publication has 45 references indexed in Scilit:
- Pathophysiology and treatment of focal segmental glomerulosclerosis: the role of animal modelsBMC Nephrology, 2013
- Glomerular Endothelial Cell Injury and Damage Precedes That of Podocytes in Adriamycin-Induced NephropathyPLOS ONE, 2013
- Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injuryAmerican Journal of Physiology-Renal Physiology, 2011
- CD4+T cells control the differentiation of Gr1+monocytes into fibrocytesProceedings of the National Academy of Sciences, 2009
- Establishment of Conditionally Immortalized Mouse Glomerular Parietal Epithelial Cells in CultureJournal of the American Society of Nephrology, 2008
- Improved Elucidation of Biological Processes Linked to Diabetic Nephropathy by Single Probe-Based Microarray Data AnalysisPLOS ONE, 2008
- Late Onset of Ccl2 Blockade with the Spiegelmer mNOX-E36–3′PEG Prevents Glomerulosclerosis and Improves Glomerular Filtration Rate in db/db MiceThe American Journal of Pathology, 2008
- The Monocyte Chemoattractant Protein-1/Cognate CC Chemokine Receptor 2 System Affects Cell Motility in Cultured Human PodocytesThe American Journal of Pathology, 2007
- Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sitesJournal of Clinical Investigation, 2007
- Comparative promoter analysis allows de novo identification of specialized cell junction-associated proteinsProceedings of the National Academy of Sciences, 2006